Santa Fe, Argentina

Instituto de Investigaciones Clinicas de Rosario

Gastroparesis

Diabetes Mellitus

Type 2 Diabetes Mellitus

Heart Failure

Atrial Fibrillation

Relamorelin

Linagliptin

EMPagliflozin

Apixaban

Empagliflozin

Glimepiride

Boehringer Ingelheim

Allergan

Janssen (J&J Innovative Medicine)

condition

allSponsorName

Bristol-Myers Squibb (BMS)

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

Instituto de Investigaciones Clinicas de Rosario | Santa Fe, Argentina

Site insights

Work at this site?

Active trials

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF)

Trial sponsors